← Back to Search

Tyrosine Kinase Inhibitor

Rifampicin + Cediranib for Solid Tumors

Phase 1
Waitlist Available
Led By Michael Sawyer, MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
WHO performance status (PS) 0-2
Prostate cancer that is refractory to standard therapies or for which no standard therapy exists
Timeline
Screening 3 weeks
Treatment Varies
Follow Up until study drug is discountinued
Awards & highlights

Study Summary

This trial is testing whether a common antibiotic can increase the effectiveness of an experimental cancer drug.

Who is the study for?
This trial is for adults with advanced solid tumors, specifically those who have prostate cancer that's not responding to standard treatments or when no standard treatment exists. Participants should be able to perform daily activities (WHO PS 0-2), expect to live at least 8 more weeks, and give written consent. People with unstable brain metastases, abnormal blood tests, significant gastrointestinal issues, or poor bone marrow function cannot join.Check my eligibility
What is being tested?
The study is examining how rifampicin affects the body's handling of cediranib in patients with advanced cancers. It's a Phase I trial which means it’s early in testing and primarily looking at safety and dosage levels of cediranib when taken alongside rifampicin.See study design
What are the potential side effects?
Cediranib may cause high blood pressure, diarrhea, fatigue, skin reactions and bleeding problems. Rifampicin can lead to liver issues, gastrointestinal discomforts like nausea or vomiting, allergic reactions and changes in blood cell counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and perform light activities.
Select...
My prostate cancer does not respond to standard treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pk assessments to be taken until day 28. days 7 and 14 pk parameters used to assess the primary variables.
This trial's timeline: 3 weeks for screening, Varies for treatment, and pk assessments to be taken until day 28. days 7 and 14 pk parameters used to assess the primary variables. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess the steady-state PK parameters of cediranib in the presence and absence of rifampicin
Secondary outcome measures
To assess the safety and tolerability of cediranib in the presence of rifampicin, by assessment of Adverse events (AEs) Laboratory findings, Vital signs, physical examination and Electrocardiogram.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
cediranib
2011
Completed Phase 3
~140

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,274 Previous Clinical Trials
288,613,300 Total Patients Enrolled
Michael Sawyer, MDPrincipal InvestigatorCross Cancer Institute, Edmonton, AB, Canada
13 Previous Clinical Trials
609 Total Patients Enrolled

Media Library

Cediranib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00750841 — Phase 1
Solid Tumors Research Study Groups: 1
Solid Tumors Clinical Trial 2023: Cediranib Highlights & Side Effects. Trial Name: NCT00750841 — Phase 1
Cediranib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00750841 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment currently available to individuals seeking out this trial?

"This particular research undertaking is no longer actively accepting patients. The trial first appeared on September 9th, 2008 and was last revised on September 20th, 2022. However there are presently 2585 clinical trials seeking participants with tumors and an additional 19 studies that allow cediranib as a medication intervention."

Answered by AI

Has there been any prior research of the same nature as this trial?

"Since 2008, cediranib has progressed through the clinical trial process. Initially sponsored by AstraZeneca and involving 64 participants, it was granted Phase 1 drug approval. Currently 19 ongoing studies are being conducted in 666 cities across 13 countries."

Answered by AI

Are my personal qualifications sufficient to join this medical research project?

"The recruitment phase of this study is searching for 64 participants who are aged between 18 and 130, with solid tumors. To qualify, they must have prostate cancer that has not responded to conventional treatments or where such therapies do not exist; be in possession of written informed consent; possess an estimated life expectancy of at least 8 weeks; and have a World Health Organization Performance Status score ranging from 0-2."

Answered by AI

Are there any other research papers concerning the application of cediranib?

"Currently, 19 studies are being conducted to examine the efficacy of cediranib. Three of these trials have progressed into Phase 3 testing. Whilst much of this research is centred in Akron, Ohio, there are 2386 institutions involved across the world."

Answered by AI

How many persons have enrolled in this experiment thus far?

"This clinical trial is no longer enrolling participants; the initial posting and most recent updates were on September 9th, 2008 and 2020 respectively. If you're seeking alternatives, there are 2585 studies relating to solid tumors recruiting patients as well 19 trials looking for cediranib candidates."

Answered by AI

Has cediranib been granted authorization by the FDA?

"Cediranib, due to its phase 1 nature, was allocated a score of one. This is because there are limited data collections verifying both safety and efficacy."

Answered by AI

Does this research study permit individuals younger than 55 to participate?

"This medical research is looking for subjects aged 18 to 130 years old."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
2008. "Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00750841.
~4 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top